

CLAIMS

What is claimed is:

1. A crystalline form of S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate characterized by at least one of: melting point of about 77.69 °C; x-ray powder pattern substantially as shown in **Fig. 15**; x-ray powder pattern substantially as shown in **Fig. 16**; unit cell as shown in **Fig. 14**; and elemental analysis substantially as in **Table 7**.
2. A pharmaceutical composition comprising the crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate Form II of claim 1 together with a pharmaceutically acceptable carrier.
3. A method of treating a condition wherein pathologically high production forms a part in a subject in need of such treatment comprising administering to the subject an effective amount of the crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate Form II of claim 1.
4. A method of decreasing nitric oxide production in a subject comprising administering to the subject an effective amount of the crystalline S-[2-[(1-Iminoethyl)amino]ethyl]-2-methyl-L-cysteine maleate Form II of claim 1.